Premier Alternatives

Convergent Therapeutics

Drug Discovery · Cambridge, MA · Founded 2020 · Privately Held (backing)

Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. Convergent Therapeutics is based in Cambridge, MA and was founded in 2020. Its last known valuation is $280 million. It has raised $130 million across 2 recorded rounds; the latest was a $22.2 million early-stage round in Jul 2024.

Last price · $/share
—
Implied valuation
$280.0M
Total raised
$130.0M
Last round
Early Stage VC
Jul 2024

Convergent Therapeutics key facts

  • Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer.
  • Convergent Therapeutics’s last known valuation is $280.0M.
  • It has raised $130.0M across 2 recorded rounds; the latest was Early Stage VC ($22.2M) in Jul 2024.
  • Notable investors include RA Capital Management, OrbiMed, Novo Holdings, The Invus Group.
  • Convergent Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Aug 2024 ($22.2M sold to 1 investors).
  • Status: Privately Held (backing).
Free account
More of Convergent Therapeutics with a free account
  • ·Watch Convergent Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Convergent Therapeutics funding rounds

2 rounds
Jul 2024Early Stage VC$22.2MSEC filing▮
May 2023Early Stage VC (Series A)$90.0M▮
Full funding history →

Convergent Therapeutics valuation

Convergent Therapeutics's last known valuation is $280 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Convergent Therapeutics raised?

Convergent Therapeutics has raised $130 million across 2 recorded rounds since 2023. The largest was a $90 million Series A in May 2023; the most recent was a $22.2 million early-stage round in Jul 2024.

Convergent Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently in Aug 2024 ($22.2 million sold to 1 investor).

Convergent Therapeutics investors

4 investors are on record for Convergent Therapeutics, including RA Capital Management, OrbiMed, Novo Holdings and The Invus Group. The early-stage round in Jul 2024 drew 1 investor.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Mythic Therapeutics ($293 million), City Therapeutics ($285 million) and Ensoma ($280 million).

About Convergent Therapeutics

Operator of a clinical-stage biotechnology company intended to explore the full potential of alpha-emitting radioantibodies to treat cancer. The company offers a proprietary platform that links humanized monoclonal antibodies targeting prostate-specific membrane antigen (PSMA) with alpha-emitting radionuclides, enabling clinicians to deliver potent, localized radiation into cancer cells while minimizing exposure to healthy tissue.

Industry
Drug Discovery
Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2020
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$280.0M

Convergent Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.